Cutaneous adverse effects in patients treated with the multitargeted kinase inhibitors sorafenib and sunitinib

Lee, W.J.; Lee, J.L.; Chang, Shun‐Hsyung; Lee, M.W.; Kang, Yoon Koo; Choi, Jin Hyuk; Moon, Kyung Chul; Koh, Jane

doi:10.1111/j.1365-2133.2009.09290.x

Cited by 204 publications

(183 citation statements)

References 28 publications

(67 reference statements)

Supporting

Mentioning

156

Contrasting

Unclassified

Order By: Relevance

“…Başlangıçta lezyonlar hassas büller şeklinde iken zamanla eritematöz yamalar haline dönüşür. Sonrasında eritematöz, kahverenkli plaklar halini alan lezyonlar son olarak hiperkeratotik kallus benzeri lezyon şeklini alır (5). Lezyonların çevresinde eritemli halo olması tipiktir.…”

Section: Discussionunclassified

Hand Foot Skin Reaction Associated with Sunitinib

Cemil¹,

Akış²,

Canpolat³

et al. 2015

tdd

View full text Add to dashboard Cite

Sunitinib renal hücreli karsinom ve gastrointestinal stromal tümörlü hastalarda yarar gösteren bir multikinaz inhibitörüdür. Sunitinib pek çok kutanöz toksisiteye yol açmaktadır. El ayak deri reaksiyonu en karakteristik ve en sık görülen kutanöz toksisitedir. Lezyonlar iyi sınırlı, özellikle basınç alanlarına lokalize ve çevresi eritem ile sınırlı sarı, ağrılı kallus benzeri hiperkeratoz ile karakterizedir. Elli dört yaşında erkek hasta renal hücreli karsinom nedeniyle başlanan 50 mg/gün oral sunitinib tedavisinin yirminci gününde el ve ayakta ağrılı döküntüleri gelişmesi nedeniyle polikliniğimize başvurdu. Dermatolojik muayenesinde avuç içi ve ayak tabanlarında çok sayıda sarı renkli, çevresi eritemli halo ile çevrili hiperkeratotik plakları mevcuttu. Hastaya tanımlayıcı klinik bulguları nedeniyle sunitinibe bağlı el ayak deri reaksiyonu tanısı kondu. El ayak deri reaksiyonu hastaların yaşam kalitesini ve tedavi dozlarını oldukça etkilemektedir. El ayak deri reaksiyonunun erken tanısı ve tedavisi ilaçtan kazanılacak maksimum etkinin sağlanmasında hayati önem taşımaktadır. Anahtar kelimeler: Antineoplastik ajanlar, El ayak sendromu, ilaç erüpsiyonu, renal hücreli karsinom, sunitinib, yan etkiler Çıkar Çatışması: Yazarlar bu makale ile ilgili olarak herhangi bir çıkar çatışması bildirmemiştir. Bengü ÇevirgenCemil, Havva Kaya Akış, Filiz Canpolat, Müzeyyen Gönül, Seda Atay, Gökşen İnanç İmamoğlu* Sunitinib ile İlişkili El Ayak Deri ReaksiyonuHand Foot Skin Reaction Associated with SunitinibSunitinib is a multi-targeted kinase inhibitor showing benefits in patients with renal cell carcinoma, and gastrointestinal stromal tumor. Sunitinib may cause various cutaneous toxicities. The most characteristic and common cutaneous toxicity is hand-foot skin reaction. Lesions are characterized by yellow painful callus like hyperkeratosis surrounded by a rim of erythema, they are well-demarcated and localized especially over pressure areas. A 54-year-old male patient with a history of renal cell carcinoma developed painful eruption twenty days after oral sunitinib had been started on 50 mg daily. Dermatological examination showed multiple, yellow, hyperkeratotic plaques with erythematous halos on palms, and soles. The patient was diagnosed as hand-foot skin reaction due to sunitinib due to descriptive clinical findings. Hand-foot skin reaction can greatly affect patients' quality of life and treatment dosages. Early diagnosis and timely treatment of hand-foot skin reaction will be vital to ensure maximum potential of these drugs.

show abstract

Section: Discussionunclassified

Hand Foot Skin Reaction Associated with Sunitinib

Cemil¹,

Akış²,

Canpolat³

et al. 2015

tdd

View full text Add to dashboard Cite

show abstract

“…Sorafenib, a bi-aryl urea class of drug with a molecular weight of 630 ug/mol [3] acts by inhibiting various kinases such as tyrosine kinase, rearranged during transfection tyrosine kinase, EGFR, vascular endothelial growth factor 2 and 3 inhibits angiogenesis, and cell proliferation [1]. In contrast to EGFR inhibitors, cutaneous drug reactions are less with sorafenib.…”

Section: Discussionmentioning

confidence: 99%

“…Cutaneous adverse reactions are common with sorafenib but acneiform eruptions are very rare, although it has a widely-reported association with epidermal growth factor receptor (EGFR) inhibition and EGFR inhibitors with incidence between 20% to 90% [1,2].…”

Section: Introductionmentioning

confidence: 99%

Sorafenib Induced Acneiform Eruptions: A Case Report

Ommurugan

Patil

2017

Asian J Pharm Clin Res

View full text Add to dashboard Cite

Sorafenib an oral tyrosine kinase inhibitor is used in the treatment of hepatocellular carcinoma, renal cell carcinoma, and thyroid cancer. Sorafenib acts by inhibiting various kinases such as tyrosine kinase, rearranged during transfection tyrosine kinase, endothelial growth factor receptor, vascular endothelial growth factor 2 and 3 inhibits angiogenesis, and cell proliferation. Acneiform eruptions are known side effect of epidermal growth factor receptor inhibitors but acneiform eruptions with sorafenib is seldom seen. Hence we report a case of sorafenib -induced acneiform eruptions.

show abstract

“…L'incidence est plus élevée avec le sunitinib et à un degré moindre avec le sorafénib [3,[9][10][11]. Elles sont globalement moins sévères qu'avec les inhibiteurs mTOR et justifient rarement l'arrêt du traitement.…”

Section: Mucites /Ulcérations Aphtoïdesunclassified

Toxicités orales des thérapies ciblées anticancéreuses

Sibaud

Vigarios

2015

Med Buccale Chir Buccale

View full text Add to dashboard Cite

Résumé -Introduction :Les thérapies ciblées anticancéreuses ont profondément modifié la prise en charge du cancer et constituent aujourd'hui un des socles thérapeutiques majeurs en oncologie. Propos : Un certain nombre de récepteurs ou voies de signalisation ciblés par ces nouvelles thérapies sont également exprimés physiologiquement par les cellules épithéliales ou du chorion de la muqueuse buccale. De nombreuses thérapies ciblées (inhibiteur BRAF, anti-EGFR ou anti-MEK, inhibiteur BCR-ABL, anti-PD1/PDL-1, inhibiteurs mTOR, molécules antiangiogéniques…) peuvent donc induire des effets indésirables muqueux variés et jusque-là assez mal individualisés. Les principales toxicités orales qui peuvent être observées avec ces nouvelles thérapies ciblées anticancéreuses sont détaillées dans cet article. Conclusion : Le spécialiste en médecine et chirurgie buccales doit savoir les reconnaître et les prendre en charge.Abstract -Oral toxicity of targeted anticancer therapies. Introduction: Targeted anticancer therapies have greatly modified management of cancer patients and currently represent one of the cornerstones of cancer treatment. Purpose: A large number of receptors or signaling pathways targeted by these new drugs are also physiologically expressed in normal cells of the oral mucosa. Therefore, some targeted therapies (BRAF inhibitors, anti-EGFR, BCR-ABL inhibitors, anti-PD1/PDL-1, mTOR inhibitors, angiogenesis inhibitors, etc. ) may induce various mucosal manifestations hitherto poorly individualized. We detail here the most representative mucosal toxicity that can be observed with these new targeted anticancer therapies. Conclusion: Physicians specialized in oral medicine and oral surgery should be aware of these new mucosal adverse events.

show abstract

Cutaneous adverse effects in patients treated with the multitargeted kinase inhibitors sorafenib and sunitinib

Abstract: Multitargeted kinase inhibitors are associated with a significant risk of various cutaneous adverse events. HFSR is the commonest and most serious cutaneous toxicity in patients treated with these drugs.

Cited by 204 publications

References 28 publications

Hand Foot Skin Reaction Associated with Sunitinib

Hand Foot Skin Reaction Associated with Sunitinib

Sorafenib Induced Acneiform Eruptions: A Case Report

Toxicités orales des thérapies ciblées anticancéreuses

Contact Info

Product

Resources

About